10-Q · May 14, 2026
SBC Medical Group Holdings reported a year-over-year revenue decline of 9.02%, totaling approximately $43.06 million, while net income fell sharply by 47.29% to $11.31 million. The company faced challenges stemming from…
Earnings analysis · 10-Q
SBC earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment data or MD&A, so current-period financial metrics cannot be reliably reported. The filing nevertheless…
Read full summary
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment data or MD&A, so current-period financial metrics cannot be reliably reported. The filing nevertheless identifies significant governance and reporting-control concerns: previously identified material weaknesses remained unremediated as of June 30, 2026, and Nasdaq issued a July 10, 2026 noncompliance notice. The principal forward-looking disclosure is a Nasdaq cure period extending to July 9, 2027, subject to an earlier deadline if the next annual meeting occurs before January 5, 2027.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control Weaknesses Remain Unremediated
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026 because previously identified material weaknesses remained unremediated.
-
Remediation Plan Continues
The company stated it remains committed to executing the remediation plan disclosed in its 2025 Form 10-K, filed March 27, 2026.
-
Defined Nasdaq Cure Period
Nasdaq provided a cure period for the company’s listing deficiencies until the earlier of the next annual meeting or July 9, 2027; if the next annual meeting occurs before January 5, 2027, compliance must be demonstrated by January 5, 2027.
-
Corporate Governance Rules Updated
The board adopted amended and restated bylaws on July 8, 2026, including updated advance-notice, universal-proxy and director-nomination requirements.
What to watch
-
Nasdaq Delisting Risk
On July 10, 2026, Nasdaq notified the company that it was not compliant with board-independence and audit-committee-size requirements under Listing Rule 5605. Failure to regain compliance by the applicable deadline could result in delisting.
-
Unremediated Internal Controls
Disclosure controls and procedures were not effective as of June 30, 2026, and the material weaknesses identified in the 2025 Annual Report remained unremediated. The company cautioned that remediation may not fully eliminate the risk of material misstatement.
-
Potential Trading and Financing Impact
If delisted and unable to list on another national exchange, the company expects reduced liquidity, limited market quotations, potential penny-stock status and reduced access to future financing.
Management's outlook
No quantitative revenue or EPS outlook was provided in the filing text supplied. The filing states that management continues remediation efforts, but provides no numeric forecast.
Earlier filings 4
10-K · April 30, 2026
SBC continues to focus on expanding its Shonan Beauty Clinic brand, executing a strategy that emphasizes acquisitions across APAC and U.S. market entry through minority investments. Fiscal 2025 reflected a substantial…
10-K · March 27, 2026
SBC positions itself as a management company for aesthetic clinics, focused on growing the Shonan Beauty Clinic brand in Japan while expanding in APAC through acquisitions and pursuing U.S. market entry via strategic…
10-Q · November 14, 2025
SBC reported Q3 revenue of $43,353,235, down $9,731,648 (−18.3%) vs. Q3 2024, while diluted EPS rose to $0.12 from $0.03 a year ago. Gross profit fell to $30,611,487 (gross margin ~70.6% vs. 81.5% in Q3 2024) but…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.